WO2006134605A1 - Amorphous esomeprazole hydrate - Google Patents

Amorphous esomeprazole hydrate Download PDF

Info

Publication number
WO2006134605A1
WO2006134605A1 PCT/IN2005/000197 IN2005000197W WO2006134605A1 WO 2006134605 A1 WO2006134605 A1 WO 2006134605A1 IN 2005000197 W IN2005000197 W IN 2005000197W WO 2006134605 A1 WO2006134605 A1 WO 2006134605A1
Authority
WO
WIPO (PCT)
Prior art keywords
esomeprazole
hydrate
amorphous
water
amorphous esomeprazole
Prior art date
Application number
PCT/IN2005/000197
Other languages
French (fr)
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Rapolu Raji Reddy
Dasari Muralidhara Reddy
Original Assignee
Hetero Drugs Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Drugs Limited filed Critical Hetero Drugs Limited
Priority to PCT/IN2005/000197 priority Critical patent/WO2006134605A1/en
Priority to US11/570,473 priority patent/US7563812B2/en
Priority to EP05760976A priority patent/EP1891043A1/en
Publication of WO2006134605A1 publication Critical patent/WO2006134605A1/en
Priority to US12/399,514 priority patent/US7638634B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

  • the present invention relates to a novel amorphous form of esomeprazole hydrate, to a process for its preparation and to a pharmaceutical composition containing it.
  • Omeprazole chemically 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2- pyridinyl)methyi]sulfinyl]-1H-benzimidazole and its therapeutic uses are disclosed in European Patent No. 5129.
  • Omeprazole is a well-known gastric acid secretion inhibitor, and is useful as an anti ulcer agent.
  • Omeprazole has a stereogenic center at sulfur and therefore exist as two optical isomers such as
  • PCT Publication No. WO 98/28294 disclosed esomeprazole in an amorphous form, a partly crystalline form A, and a substantially crystalline form
  • PCT Publication No. WO 2004/076440 A1 described crystalline forms, Form I and Form II, of esomeprazole, and its hydrates.
  • PCT Publication No. WO 2004/076440 A1 described crystalline forms, Form I and Form II, of esomeprazole, and its hydrates.
  • PCT Publication No. WO 2004/076440 A1 described crystalline forms, Form I and Form II, of esomeprazole, and its hydrates.
  • novel amorphous form of esomeprazole hydrate is stable over the time and has good flow properties and so, the novel amorphous hydrate is suitable for formulating esomeprazole.
  • the object of the present invention is to provide a stable novel amorphous form of esomeprazole hydrate, process for preparing it and pharmaceutical composition containing it.
  • a novel amorphous form of esomeprazole hydrate is provided.
  • the water content of the amorphous form of esomeprazole hydrate is between 3.0 and 5.0% by weight of amorphous form of esomeprazole hydrate, typically between 3.5 and 4.5% by weight of amorphous form of esomeprazole hydrate.
  • amorphous form of esomeprazole hydrate is characterized by having broad X-ray diffraction spectrum as shown in figure I.
  • a process is provided for the preparation of amorphous esomeprazole hydrate, which comprises: a) providing a solution of esomeprazole in the mixture of water and a solvent or a mixture of solvents selected from tetrahydrofuran, acetonitrile, 1 ,4-dioxane and dimethyl formamide; and b) precipitating amorphous esomeprazole hydrate from the solution.
  • the solution of esomeprazole may be prepared by dissolving esomeprazole in a mixture of water and the solvent or by dissolving esomeprazole in the solvent and then adding water to the solution.
  • the solution of esomeprazole may also be prepared by adding an acid to a salt of esomeprazole in the presence of water and the solvent to obtain a solution of esomeprazole.
  • the ratio of water to the solvent is maintained at 0.5 : 1 to 4 : 1 by volume, preferably at 1 : 1 to 3 : 1 by volume and more preferably at 1.5 : 1 to 2.5 : 1 by volume.
  • the precipitation of amorphous esomeprazole hydrate may be carried out by conventional methods such as cooling, • seeding, partial removal of solvent, addition of extra quantity of water or a combination thereof.
  • the precipitated amorphous esomeprazole hydrate may be collected by filtration or centrifugation and then dried. The drying may preferably carried out at about 20 - 35 0 C in rotovapour.
  • the amorphous esomeprazole hydrate is novel and forms part of the invention. Amorphous esomeprazole hydrate may be used in pharmaceutical preparations. Amorphous esomeprazole hydrate is useful intermediate for preparing amorphous or crystalline anhydrous esomeprazole.
  • Amorphous esomeprazole hydrate may, for example, be converted to amorphous esomeprazole by slurring with an insoluble solvent.
  • Esomeprazole hydrate may also be useful intermediate for preparation of known pharmaceutically acceptable salts by conventional means.
  • the above process may be used to purify crude esomeprazole or a crude esomeprazole salt by providing a solution of crude esomeprazole and precipitating pure esomeprazole hydrate as described above.
  • the pure amorphous esomeprazole hydrate obtained is optionally converted to anhydrous esomeprazole by a method such as slurrying in an organic solvent and filtering to obtain anhydrous esomeprazole.
  • Crude esomeprazole refers to esomeprazole for which further treatment is required to get esomeprazole of desired purity (pure esomeprazole).
  • a pharmaceutical composition comprising amorphous esomeprazole hydrate and a pharmaceutically acceptable carrier.
  • Preferable pharmaceutical composition is a solid oral dosage form.
  • Figure 1 is an X-ray powder diffraction pattern of amorphous esomeprazole hydrate.
  • X-Ray powder diffraction spectrum was measured on a Bruker axs D8 advance x-ray powder diffractometer having a Copper-K ⁇ radiation. Approximately 1 gm of sample was gently flattened on a sample holder and scanned from 2 to 50 degrees two-theta, at 0.03 degrees two-theta per step and a step time of 0.5 seconds. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40 KV and current 35 mA.
  • the following examples are given for the purpose of illustrating the present invention and should not be considered as limitations on the scope or spirit of the invention.
  • Tetrahydrofuran (250 ml) and water (500 ml) are added to esomeprazole potassium salt (50 gm) at 25 - 30 0 C, cooled to 20 0 C and then the pH is adjusted to 7.5 - 8.0 with acetic acid.
  • the reaction mass is cooled to 5 0 C, stirred for 2 to 3 hours at 0 - 5 0 C, filtered the mass, washed with 50 ml of chilled mixture of water and tetrahydrofuran (2 : 1) and again washed with water (100 ml).
  • the wet cake is dried at 30 - 35 0 C under vacuum to reach the moisture content to 25 - 30%.
  • the solid is again dried in rotovapour at 25 - 3O 0 C under nitrogen atmosphere to give 26.3 gm of amorphous esomeprazole hydrate (HPLC Purity: 99.92%, Moisture Content: 4.0%).
  • Acetonitrile (250 ml) and water (700 ml) are added to esomeprazole potassium salt (50 gm) at 25 - 3O 0 C, cooled to 20 0 C and then the pH is adjusted to 7.5 - 8.0 with acetic acid.
  • the reaction mass is cooled to 5°C, stirred for 2 to 3 hours at 0 - 5 0 C, filtered the mass, washed with 50 ml of chilled mixture of water and acetonitrile (3 :1) and again washed with water (100 ml).
  • the wet cake is dried at 30 - 35 0 C to reach the moisture content to 30 - 35%.
  • the solid is again dried in rotovapour at 25 - 3O 0 C under nitrogen atmosphere to give 26.1 gm of amorphous esomeprazole hydrate (HPLC Purity: 99.91%, Moisture Content: 4.1%).

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to a novel amorphous form of esomeprazole hydrate, to a process for its preparation and to a pharmaceutical composition containing it. Thus, tetrahydrofuran and water are added to esomeprazole potassium salt at 25 - 30°C, cooled to 20°C and then the pH is adjusted to 7.5 - 8.0 with acetic acid. The reaction mass is cooled to 5°C, stirred for 2 to 3 hours at 0 - 5°C, filtered the mass, washed with chilled mixture of water and tetrahydrofuran (2 : 1), and again washed with water. The wet cake is dried at 30 - 35°C under vacuum to reach the moisture content to 25 - 30%. The solid is again dried in rotovapour at 25 - 30°C under nitrogen atmosphere to give amorphous esomeprazole hydrate.

Description

AMORPHOUS ESOMEPRAZOLE HYDRATE
FIELD OF THE INVENTION
The present invention relates to a novel amorphous form of esomeprazole hydrate, to a process for its preparation and to a pharmaceutical composition containing it.
BACKGROUND OF THE INVENTION
Omeprazole, chemically 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2- pyridinyl)methyi]sulfinyl]-1H-benzimidazole and its therapeutic uses are disclosed in European Patent No. 5129. Omeprazole is a well-known gastric acid secretion inhibitor, and is useful as an anti ulcer agent. Omeprazole has a stereogenic center at sulfur and therefore exist as two optical isomers such as
R-omeprazole and S-omeprazole (esomeprazole). The salts of the enantiomers of omeprazole are described in WO
94/27988. PCT Publication No. WO 98/28294 disclosed esomeprazole in an amorphous form, a partly crystalline form A, and a substantially crystalline form
B.
PCT Publication No. WO 2004/076440 A1 described crystalline forms, Form I and Form II, of esomeprazole, and its hydrates. PCT Publication No. WO
2004/020436 A1 described amorphous hydrates of esomeprazole magnesium and process for their preparation. PCT Publication No. WO 2004/002982 A2 described amorphous form esomeprazole free base and process for its preparation. U.S. Patent No. 6,369,085 described crystalline forms of esomeprazole magnesium, esomeprazole magnesium dihydrate, esomeprazole magnesium trihydrate and esomeprazole potassium.
The alkaline salts of (S)-enantiomer of omeprazole (esomeprazole), the pharmaceutical preparations of these salts and the method of treatment of gastric acid-related diseases using them are disclosed in US 4,738,974, US
5,877,192 and US 5,714,504.
We have discovered a stable novel amorphous form of esomeprazole hydrate. The novel amorphous esomeprazole hydrate is stable over the time and has good flow properties and so, the novel amorphous hydrate is suitable for formulating esomeprazole.
The object of the present invention is to provide a stable novel amorphous form of esomeprazole hydrate, process for preparing it and pharmaceutical composition containing it.
DETAILED DESCRIPTION OF THE INVENTION In accordance with the present invention, there is provided a novel amorphous form of esomeprazole hydrate. The water content of the amorphous form of esomeprazole hydrate is between 3.0 and 5.0% by weight of amorphous form of esomeprazole hydrate, typically between 3.5 and 4.5% by weight of amorphous form of esomeprazole hydrate.
The amorphous form of esomeprazole hydrate, designated as amorphous esomeprazole hydrate, is characterized by having broad X-ray diffraction spectrum as shown in figure I. According to one aspect of the present invention, a process is provided for the preparation of amorphous esomeprazole hydrate, which comprises: a) providing a solution of esomeprazole in the mixture of water and a solvent or a mixture of solvents selected from tetrahydrofuran, acetonitrile, 1 ,4-dioxane and dimethyl formamide; and b) precipitating amorphous esomeprazole hydrate from the solution.
The solution of esomeprazole may be prepared by dissolving esomeprazole in a mixture of water and the solvent or by dissolving esomeprazole in the solvent and then adding water to the solution.
The solution of esomeprazole may also be prepared by adding an acid to a salt of esomeprazole in the presence of water and the solvent to obtain a solution of esomeprazole.
During precipitation the ratio of water to the solvent is maintained at 0.5 : 1 to 4 : 1 by volume, preferably at 1 : 1 to 3 : 1 by volume and more preferably at 1.5 : 1 to 2.5 : 1 by volume. The precipitation of amorphous esomeprazole hydrate may be carried out by conventional methods such as cooling, • seeding, partial removal of solvent, addition of extra quantity of water or a combination thereof.
The precipitated amorphous esomeprazole hydrate may be collected by filtration or centrifugation and then dried. The drying may preferably carried out at about 20 - 350C in rotovapour. The amorphous esomeprazole hydrate is novel and forms part of the invention. Amorphous esomeprazole hydrate may be used in pharmaceutical preparations. Amorphous esomeprazole hydrate is useful intermediate for preparing amorphous or crystalline anhydrous esomeprazole.
Amorphous esomeprazole hydrate may, for example, be converted to amorphous esomeprazole by slurring with an insoluble solvent.
Esomeprazole hydrate may also be useful intermediate for preparation of known pharmaceutically acceptable salts by conventional means.
The above process may be used to purify crude esomeprazole or a crude esomeprazole salt by providing a solution of crude esomeprazole and precipitating pure esomeprazole hydrate as described above. The pure amorphous esomeprazole hydrate obtained is optionally converted to anhydrous esomeprazole by a method such as slurrying in an organic solvent and filtering to obtain anhydrous esomeprazole.
Crude esomeprazole refers to esomeprazole for which further treatment is required to get esomeprazole of desired purity (pure esomeprazole).
According to another aspect of the present invention there is provided a pharmaceutical composition comprising amorphous esomeprazole hydrate and a pharmaceutically acceptable carrier. Preferable pharmaceutical composition is a solid oral dosage form.
BRIEF DESCRIPTION OF THE DRAWING
Figure 1 is an X-ray powder diffraction pattern of amorphous esomeprazole hydrate.
X-Ray powder diffraction spectrum was measured on a Bruker axs D8 advance x-ray powder diffractometer having a Copper-Kα radiation. Approximately 1 gm of sample was gently flattened on a sample holder and scanned from 2 to 50 degrees two-theta, at 0.03 degrees two-theta per step and a step time of 0.5 seconds. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40 KV and current 35 mA. The following examples are given for the purpose of illustrating the present invention and should not be considered as limitations on the scope or spirit of the invention.
Example 1
Tetrahydrofuran (250 ml) and water (500 ml) are added to esomeprazole potassium salt (50 gm) at 25 - 300C, cooled to 200C and then the pH is adjusted to 7.5 - 8.0 with acetic acid. The reaction mass is cooled to 50C, stirred for 2 to 3 hours at 0 - 50C, filtered the mass, washed with 50 ml of chilled mixture of water and tetrahydrofuran (2 : 1) and again washed with water (100 ml). The wet cake is dried at 30 - 350C under vacuum to reach the moisture content to 25 - 30%. The solid is again dried in rotovapour at 25 - 3O0C under nitrogen atmosphere to give 26.3 gm of amorphous esomeprazole hydrate (HPLC Purity: 99.92%, Moisture Content: 4.0%).
Example 2
Acetonitrile (250 ml) and water (700 ml) are added to esomeprazole potassium salt (50 gm) at 25 - 3O0C, cooled to 200C and then the pH is adjusted to 7.5 - 8.0 with acetic acid. The reaction mass is cooled to 5°C, stirred for 2 to 3 hours at 0 - 50C, filtered the mass, washed with 50 ml of chilled mixture of water and acetonitrile (3 :1) and again washed with water (100 ml). The wet cake is dried at 30 - 350C to reach the moisture content to 30 - 35%. The solid is again dried in rotovapour at 25 - 3O0C under nitrogen atmosphere to give 26.1 gm of amorphous esomeprazole hydrate (HPLC Purity: 99.91%, Moisture Content: 4.1%).

Claims

We claim:
1. Amorphous esomeprazole hydrate.
2. An amorphous esomeprazole hydrate as defined in claim 1 , wherein the water content of the amorphous esomeprazole hydrate is between 3.0 and 5.0% by weight of amorphous esomeprazole hydrate.
3. An amorphous esomeprazole hydrate as defined in claim 2, wherein the water content of the amorphous esomeprazole hydrate is between 3.5 and 4.5% by weight of amorphous esomeprazole hydrate.
4. A process for preparation of amorphous esomeprazole hydrate of claim 1 , which comprises: a) providing a solution of esomeprazole in the mixture of water; and a solvent or mixture of solvents selected from tetrahydrofuran, acetonitrile, 1 ,4-dioxane and dimethylformamide; and b) precipitating amorphous esomeprazole hydrate from the solution. 5. The process as claimed in claim 4, wherein the ratio of water to the solvent during precipitation is maintained at 0.
5 : 1 to 4 : 1 by volume.
6. The process as claimed in claim 5, wherein the ratio of water to the solvent during precipitation is maintained at 1 : 1 to 3 : 1 by volume.
7. The process as claimed in claim 6, wherein the ratio of water to the solvent during precipitation is maintained at 1.5 : 1 to 2.5 : 1 by volume.
8. The process as claimed in claim 4, wherein the precipitation of amorphous esomeprazole hydrate is carried out by cooling, seeding, partial removal of solvent, addition of extra quantity of water or a combination thereof.
9. The process as claimed in claim 8, further comprises the precipitated amorphous esomeprazole hydrate is collected by filtration or centrifugation and then dried.
10. The process as claimed in claim 9, wherein the drying is carried out at about 20 - 350C in rotovapour.
11. A pharmaceutical composition comprising amorphous esomeprazole hydrate of claim 1 and a pharmaceutically acceptable excipient.
12. The pharmaceutical composition as claimed in claim 11 , wherein the pharmaceutical composition is a solid oral dosage form.
PCT/IN2005/000197 2005-06-15 2005-06-15 Amorphous esomeprazole hydrate WO2006134605A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/IN2005/000197 WO2006134605A1 (en) 2005-06-15 2005-06-15 Amorphous esomeprazole hydrate
US11/570,473 US7563812B2 (en) 2005-06-15 2005-06-15 Amorphous esomeprazole hydrate
EP05760976A EP1891043A1 (en) 2005-06-15 2005-06-15 Amorphous esomeprazole hydrate
US12/399,514 US7638634B2 (en) 2005-06-15 2009-03-06 Amorphous esomeprazole hydrate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2005/000197 WO2006134605A1 (en) 2005-06-15 2005-06-15 Amorphous esomeprazole hydrate

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/570,473 A-371-Of-International US7563812B2 (en) 2005-06-15 2005-06-15 Amorphous esomeprazole hydrate
US12/399,514 Division US7638634B2 (en) 2005-06-15 2009-03-06 Amorphous esomeprazole hydrate

Publications (1)

Publication Number Publication Date
WO2006134605A1 true WO2006134605A1 (en) 2006-12-21

Family

ID=37531990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000197 WO2006134605A1 (en) 2005-06-15 2005-06-15 Amorphous esomeprazole hydrate

Country Status (3)

Country Link
US (2) US7563812B2 (en)
EP (1) EP1891043A1 (en)
WO (1) WO2006134605A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527355A3 (en) * 2005-04-25 2014-05-07 Genaera Corporation Polymorphic and amorphous salt forms of squalamine dilactate
CN104086531A (en) * 2014-07-17 2014-10-08 长沙市华美医药科技有限公司 Esomeprazole sodium compound and pharmaceutical composition thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE538108T1 (en) * 2006-11-05 2012-01-15 Max Planck Gesellschaft THIAZOLE HYDRAZIDES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028294A1 (en) * 1996-12-20 1998-07-02 Astra Aktiebolag A novel compound form
WO2004002982A2 (en) * 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (en) 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
SE8301182D0 (en) 1983-03-04 1983-03-04 Haessle Ab NOVEL COMPOUNDS
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (en) 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
SE510650C2 (en) 1997-05-30 1999-06-14 Astra Ab New association
US7612098B2 (en) 2002-08-30 2009-11-03 Dr. Reddy's Laboratories Limited Amorphous hydrous esomeprazole magnesium
CN1777598A (en) 2003-02-28 2006-05-24 兰贝克赛实验室有限公司 Polymorphs of s-omeprazole.
US20070141424A1 (en) 2005-12-21 2007-06-21 Armstrong Timothy R Solid oxide fuel cell and stack configuration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028294A1 (en) * 1996-12-20 1998-07-02 Astra Aktiebolag A novel compound form
WO2004002982A2 (en) * 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527355A3 (en) * 2005-04-25 2014-05-07 Genaera Corporation Polymorphic and amorphous salt forms of squalamine dilactate
CN104086531A (en) * 2014-07-17 2014-10-08 长沙市华美医药科技有限公司 Esomeprazole sodium compound and pharmaceutical composition thereof

Also Published As

Publication number Publication date
EP1891043A1 (en) 2008-02-27
US20080293773A1 (en) 2008-11-27
US7638634B2 (en) 2009-12-29
US7563812B2 (en) 2009-07-21
US20090198066A1 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
US8106210B2 (en) Polymorphs of esomeprazole salts
JP2001507025A (en) New compound forms
SA05260296B1 (en) A new process for preparing the trihydrate of the magnesium salt from S-omeprazole
WO2008045777A2 (en) A process for the preparation of benzimidazole derivatives and their salts
US7638634B2 (en) Amorphous esomeprazole hydrate
AU2005257709B2 (en) New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
WO2011004387A2 (en) Process for the preparation of dexlansoprazole polymorphic forms
JP2011236210A (en) Precursor phase and use thereof for preparing magnesium tetrahydrate salt of omeprazole enantiomer
JP2014169302A (en) Solid form of the magnesium salt of (s)-omeprazole and method for manufacturing the same
ZA200507009B (en) Polymorphs of S-omerprazole
EP1893602A2 (en) Pantoprazole free acid form iii
US20100267959A1 (en) Process for the preparation of esomeprazole magnesium dihydrate
CA2504796A1 (en) Polymorphs of pantoprazole sodium salt and process for the preparation thereof
WO2008017020A2 (en) Process for preparing proton pump inhibitors
US8552193B2 (en) Alternative forms of the phosphodiesterase-4 inhibitor N-cyclopropyl-1-{3-[(1-oxidopryidin-3-yl)ethynyl]phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxyamide
US8124779B2 (en) Process for the preparation of esomeprazole non-salt form
WO2005082888A1 (en) Process for the preparation of magnesium salt of omeprazole
EP1948637A1 (en) Process for amorphous esomeprazole
EP2000468A1 (en) Esomeprazole salts and processes for preparation thereof
WO2008068767A2 (en) A novel crystalline form of lansoprazole
MXPA99010945A (en) Novel form of s

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 3472/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 11570473

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005760976

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWP Wipo information: published in national office

Ref document number: 2005760976

Country of ref document: EP